[go: up one dir, main page]

MX2016011938A - Composicion farmaceutica liquida. - Google Patents

Composicion farmaceutica liquida.

Info

Publication number
MX2016011938A
MX2016011938A MX2016011938A MX2016011938A MX2016011938A MX 2016011938 A MX2016011938 A MX 2016011938A MX 2016011938 A MX2016011938 A MX 2016011938A MX 2016011938 A MX2016011938 A MX 2016011938A MX 2016011938 A MX2016011938 A MX 2016011938A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
provides
magnesium oxide
present
Prior art date
Application number
MX2016011938A
Other languages
English (en)
Other versions
MX366499B (es
Inventor
Gil Nam Bong
Original Assignee
Pharmbio Korea Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51742358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016011938(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmbio Korea Co Ltd filed Critical Pharmbio Korea Co Ltd
Publication of MX2016011938A publication Critical patent/MX2016011938A/es
Publication of MX366499B publication Critical patent/MX366499B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una composición farmacéutica líquida fisicoquímicamente estable, la cual comprende picosulfato de sodio, óxido de magnesio, ácido cítrico y ácido málico.
MX2016011938A 2014-03-19 2014-06-23 Composicion farmaceutica liquida. MX366499B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140032242A KR101420315B1 (ko) 2014-03-19 2014-03-19 약학적 액제 조성물
PCT/KR2014/005512 WO2015141897A1 (ko) 2014-03-19 2014-06-23 약학적 액제 조성물

Publications (2)

Publication Number Publication Date
MX2016011938A true MX2016011938A (es) 2017-05-30
MX366499B MX366499B (es) 2019-07-11

Family

ID=51742358

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011938A MX366499B (es) 2014-03-19 2014-06-23 Composicion farmaceutica liquida.

Country Status (11)

Country Link
US (4) US9827231B2 (es)
EP (1) EP3120835B1 (es)
JP (1) JP6347891B2 (es)
KR (1) KR101420315B1 (es)
CN (1) CN106456534B (es)
AU (1) AU2014386903B2 (es)
CA (1) CA2942878C (es)
ES (1) ES2907324T3 (es)
MX (1) MX366499B (es)
RU (1) RU2668882C2 (es)
WO (1) WO2015141897A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101420315B1 (ko) 2014-03-19 2014-07-17 남봉길 약학적 액제 조성물
RU2018105869A (ru) * 2015-08-17 2019-09-19 Ферринг Б.В. Жидкие составы, содержащие пикосульфат и цитрат магния
EP3409290A4 (en) * 2016-01-28 2019-09-18 CTC Bio, Inc. DISPOSABLE COMPOSITION
AR108992A1 (es) * 2016-07-08 2018-10-17 Ferring Bv Formulaciones líquidas estabilizadas que contienen picosulfato
KR101839773B1 (ko) 2016-12-07 2018-03-19 (주)대명산업 해초제거제
KR101960268B1 (ko) * 2017-01-04 2019-03-21 어업회사법인 블루오션(주) 녹조류 제거제
US11471447B2 (en) 2019-06-20 2022-10-18 Hetero Labs Limited Stable pharmaceutical product and vessel comprising sodium picosulfate, magnesium oxide and citric acid
CN116585261B (zh) * 2023-05-17 2024-05-14 深圳市贝美药业有限公司 药物液体组合物及其制备方法和应用
WO2025093697A1 (en) 2023-11-03 2025-05-08 Casen Recordati S.L. Ready-to-use laxative liquid pharmaceutical composition and process for its preparation
CN117338709B (zh) * 2023-11-07 2025-08-22 浙江和沐康医药科技有限公司 一种复方匹可硫酸钠口服溶液及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5697248A (en) 1979-12-28 1981-08-05 Tanaka Shiro Conjugated compound of calcium citrate and calcium malate and its preparation
US5010069A (en) 1989-05-15 1991-04-23 Marion Laboratories, Inc. Stable liquid form of 5-aminosalicylic acid
FR2647347A1 (fr) 1989-05-24 1990-11-30 Lucien Laboratoires Agents et complexes de l'ion mg2+ facilitant l'absorption du magnesium dans un organisme humain ou animal, et compositions pharmaceutiques ou dietetiques utilisables pour l'administration de magnesium dans un organisme humain ou animal
JP2557111B2 (ja) 1989-11-27 1996-11-27 フジックス 株式会社 高濃度のマグネシウム溶液の製造方法及びそれによって得られたマグネシウム溶液並びにその用途
CA2085008C (en) 1990-06-14 1998-08-18 Mary M. Fox Calcium citrate malate composition
WO1992007475A1 (en) 1990-10-31 1992-05-14 The Procter & Gamble Company Calcium fortified sauces
JP2930737B2 (ja) 1990-12-27 1999-08-03 雪印乳業株式会社 カルシウム強化食品およびその製造方法
US5498425A (en) * 1995-03-17 1996-03-12 Block Drug Company, Inc. Phosphosoda buffered saline laxative
JPH10327805A (ja) 1997-06-02 1998-12-15 Yasuma Kk マグネシウム含有食品組成物
JPH11299454A (ja) 1998-04-27 1999-11-02 Sankyo Foods Kk ドロマイトの可溶化方法
WO2001066083A1 (fr) 2000-03-10 2001-09-13 Taisho Pharmaceutical Co., Ltd. Preparations de gels destinees a une administration par voie orale a proprietes de conservation ameliorees
JP4245821B2 (ja) 2000-04-28 2009-04-02 協和発酵バイオ株式会社 カルシウムおよびマグネシウム溶液及びそれを含有する飲食品並びにそれらの製造方法
GB0224909D0 (en) * 2002-10-25 2002-12-04 Norgine Europe Bv Colon cleansing compositions
GB0307918D0 (en) * 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
US7382110B2 (en) 2004-04-23 2008-06-03 Sony Corporation Method of charging secondary battery, method of calculating remaining capacity rate of secondary battery, and battery pack
IN2006CH01605A (es) 2006-09-05 2008-11-28 Global Calcium Pvt Ltd
HUE038174T2 (hu) * 2007-10-12 2018-09-28 Ferring Int Center Sa Eljárás citromsavat, magnéziumoxidot, káliumbikarbonátot és nátriumpikoszulfátot tartalmazó gyógyszertermék elõállítására, ilyen eljárással elõállított szemcsés gyógyászati készítmény és köztitermékei
EA201001328A1 (ru) * 2008-02-19 2011-04-29 Марвел Лайфсайнсез Лтд. Оральные дозированные композиции и способ их получения
JP2009263298A (ja) * 2008-04-28 2009-11-12 Ss Pharmaceut Co Ltd 不快な味を隠ぺいした経口組成物
EP2515858A1 (en) * 2009-12-25 2012-10-31 Mahmut Bilgic Pharmaceutical composition with high purity
EP2568959A2 (en) * 2010-05-14 2013-03-20 Mahmut Bilgic Formulations comprising a third generation cephalosporin and clavulanic acid
WO2012102799A2 (en) * 2011-01-28 2012-08-02 Shaver William A Method, composition and package for bowel cleansing
AU2012284200B2 (en) 2011-07-15 2016-09-22 Ferring B.V. Method for timing a colonoscopy wherein a picosulate composition is administered
US9238075B2 (en) * 2011-12-07 2016-01-19 Msm Innovations, Inc. Method for bowel preparation
KR101155099B1 (ko) 2012-03-29 2012-06-11 남봉길 장 세척용 조성물의 제조 방법 및 이에 의해 제조된 장 세척용 조성물
ES2717282T3 (es) 2012-07-27 2019-06-20 Redhill Biopharma Ltd Formulaciones y métodos para fabricar formulaciones para su uso en la evacuación colónica
BR112015004165A2 (pt) * 2012-08-29 2017-07-04 Salix Pharmaceuticals Inc métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas
AR092500A1 (es) * 2012-09-11 2015-04-22 Norgine Bv Solucion de limpieza de colon
KR101517520B1 (ko) * 2013-08-05 2015-05-04 이희엽 피코황산나트륨 함유 장 세척용 조성물의 제조방법
IN2013MU02911A (es) 2013-09-10 2015-07-03 Cadila Healthcare Ltd
KR101420315B1 (ko) 2014-03-19 2014-07-17 남봉길 약학적 액제 조성물
RU2018105869A (ru) 2015-08-17 2019-09-19 Ферринг Б.В. Жидкие составы, содержащие пикосульфат и цитрат магния
AR108992A1 (es) 2016-07-08 2018-10-17 Ferring Bv Formulaciones líquidas estabilizadas que contienen picosulfato

Also Published As

Publication number Publication date
US20180235947A1 (en) 2018-08-23
WO2015141897A1 (ko) 2015-09-24
CN106456534B (zh) 2019-05-14
US20200345708A1 (en) 2020-11-05
ES2907324T3 (es) 2022-04-22
JP2017508815A (ja) 2017-03-30
AU2014386903A1 (en) 2016-11-03
KR101420315B1 (ko) 2014-07-17
US20220193052A1 (en) 2022-06-23
AU2014386903B2 (en) 2020-01-30
US9827231B2 (en) 2017-11-28
CA2942878A1 (en) 2015-09-24
RU2016138577A (ru) 2018-04-20
EP3120835B1 (en) 2021-12-08
JP6347891B2 (ja) 2018-06-27
US20160324837A1 (en) 2016-11-10
US11191753B2 (en) 2021-12-07
US10624879B2 (en) 2020-04-21
EP3120835A4 (en) 2017-10-18
RU2668882C2 (ru) 2018-10-04
MX366499B (es) 2019-07-11
CN106456534A (zh) 2017-02-22
EP3120835A1 (en) 2017-01-25
CA2942878C (en) 2021-08-24

Similar Documents

Publication Publication Date Title
MX366499B (es) Composicion farmaceutica liquida.
PH12018500894A1 (en) Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
MX2017002969A (es) Composiciones detergentes que contienen un surfactante ramificado.
GEP20217239B (en) Pharmaceutical composition
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
EP3135293A4 (en) Agent for preventing or ameliorating diabetes
MX2017009653A (es) Composicion de bebida en polvo.
IN2014MU01248A (es)
PH12017502028A1 (en) Vortioxetine pyroglutamate
GEP20217240B (en) Pharmaceutical composition
ZA201905379B (en) 1-amino-1-cyclopropanecaboxylic acid formulations
PL3645016T3 (pl) Połączenie zawierające tlen i kwas hialuronowy do stosowania miejscowego-dopochwowego
MY183068A (en) Pharmaceutical formulation comprising antibody
IL252683A0 (en) Pyridyl-cycloalkyl-substituted carboxylic acids, preparations containing them and their medical uses
SG10201900598TA (en) Factor viii formulation
PL3223611T3 (pl) Dwuskładnikowa kompozycja dezynfekująca zawierająca kwas nadoctowy i środek chelatujący
MX2016011401A (es) Composiciones farmaceuticas que comprenden levocetirizina.
AU2016361427A8 (en) Platinum anticancer agents
IN2014CH00840A (es)
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
MA40027A (fr) Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique
EP3533448A4 (en) STABLE PHARMACEUTICAL COMPOSITION
IL266659B (en) fgfr4 inhibitor, a pharmaceutical preparation containing it and its use
EP3183231A4 (en) Perfume compositons containing isomeric alkadienenitriles

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: FERRING INTERNATIONAL CENTER SA

FG Grant or registration